CN103232394B - 含吡唑类化合物、其制备方法和用途 - Google Patents
含吡唑类化合物、其制备方法和用途 Download PDFInfo
- Publication number
- CN103232394B CN103232394B CN201310192334.9A CN201310192334A CN103232394B CN 103232394 B CN103232394 B CN 103232394B CN 201310192334 A CN201310192334 A CN 201310192334A CN 103232394 B CN103232394 B CN 103232394B
- Authority
- CN
- China
- Prior art keywords
- compound
- general formula
- preparation
- phenyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 4
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 abstract description 7
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 13
- 238000007873 sieving Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000001035 drying Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940090044 injection Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940126672 traditional medicines Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JNELGWHKGNBSMD-UHFFFAOYSA-N xanthone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3OC2=C1 JNELGWHKGNBSMD-UHFFFAOYSA-N 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940081995 fluorouracil injection Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及抗癌相关的药物领域。具体而言，本发明涉及具有通式I的、有抗肿瘤性能的吡唑类衍生物及其制备方法、药物组合物及用途。
Description
技术领域
本发明涉及抗肿瘤相关的药物领域。具体而言，本发明涉及具有抗肿瘤作用的吡唑类衍生物及其制备方法，以及含有它们的药物组合物。
背景技术
癌症是威胁人类生命的首要疾病，据统计，每年全球癌症死亡总数达700万人，我国每年死于肿瘤的患者100多万人，并逐渐增加，已成为城市人口的第一位死因。目前在我国临床上传统的治疗癌症疾病的药物有很多，它们在临床上治疗效果也较明显，但是缺点在于：特异性低，选择性差，导致明显的毒副作用，容易产生严重的癌症多药耐药现象。
随着分子生物学的发展，当今抗癌症药物正从传统的细胞毒性药物，向针对机制的多环节作用的新型抗癌症药物发展，目前国内外关注的抗癌作用的新靶点中重要之一就是蛋白酪氨酸激酶(黄敏，丁健，抗肿瘤药物新靶点，《中国处方药》，2006，12(57)，10-15)。蛋白酪氨酸激酶目前有超过20个分属不同家族的受体和非受体酪氨酸激酶被作为靶标进行抗癌药物筛选，其抑制剂已经有几个上市，为了寻找活性更好的药物，近年来分子靶向抗癌药物治疗又提出另一个挑战性概念：多靶标酪氨酸激酶抑制(multiple targeted tyrosine kinase inhibition)的策略，是抗肿瘤的重要的方向。
本发明公开了一类含有吡唑结构的蛋白酪氨酸激酶抑制剂，可以用于制备抗肿瘤药物。
发明内容
本发明的一个目的是提供一种具有通式I的含有吡唑结构的蛋白酪氨酸激酶抑制剂。
本发明的另一个目的是提供制备具有通式I的化合物的方法。
本发明的再一个目的是提供含有通式I的化合物作为有效成分，以及一种或多种药学上可接受的载体、赋形剂或稀释剂的药用组合物，及其在抗肿瘤方面的应用。
现结合本发明的目的对本发明内容进行具体描述。
本发明具有通式I的化合物具有下述结构式：
其中，
R1和R2独立地选自H，C1-C5的烷基，苯基，被F、Cl、Br、I、CN、NO2、C1-C5的烷基取代的苯基；
n＝0-5。
优选以下通式I化合物，
其中，
R1和R2独立地选自H，C1-C3的烷基，苯基，被F、Cl、CN、NO2、C1-C3的烷基取代的苯基；
n＝1-3。
更优选的本发明具有通式I的化合物如下所示：
本发明所述通式I化合物通过以下步骤合成：
化合物A和化合物B在碱存在下在合适的溶剂中反应，可以得到化合物I。
其中所述碱选自三乙胺、二异丙基乙基胺、KOH、NaOH、碳酸钾、碳酸钠、乙醇钠、氢化钠，溶剂选自三氯甲烷、二氯甲烷、乙腈、DMF等。该反应可以使用碘盐作为催化剂，如KI和NaI等。
本发明所述式I化合物，可以与一种或多种药学上可接受的载体、赋形剂或稀释剂共同制成药物组合物。该药物组合物可以制成固体口服制剂、液体口服制剂、注射剂等剂型。所述固体及液体口服制剂包括：片剂、分散片、糖衣剂、颗粒剂、干粉剂、胶囊剂和溶液剂。所述的注射剂包括：小针、大输液、冻干粉针等。
本发明的组合物，所述的药学或食品学上可接受辅料选自：填充剂、崩解剂、润滑剂、助流剂、泡腾剂、矫味剂、防腐剂、包衣材料、或其它赋形剂。
本发明的组合物，所述的药学或食品学上可接受辅料。填充剂包括乳糖、蔗糖、糊精、淀粉、预胶化淀粉、甘露醇、山梨醇、磷酸氢钙、硫酸钙、碳酸钙、微晶纤维素的一种或几种的组合物；所述的粘合剂包括蔗糖、淀粉、聚维酮、羧甲基纤维素钠、羟丙甲纤维素、羟丙纤维素、甲基纤维素、聚乙二醇、药用乙醇、水的一种或几种的组合物；所述的崩解剂包括淀粉、交联聚微酮、交联羧甲基纤维素钠、低取代羟丙基纤维素、羧甲纤维素钠、泡腾崩解剂的一种或几种的组合物。
本发明所述通式I化合物具有针对癌症的抑制作用，可作为有效成分用于制备癌症方面的治疗药物。本发明所述通式I化合物的活性是通过体外抗肿瘤模型验证的。
本发明的通式I化合物在相当宽的剂量范围内是有效的。实际服用本发明通式I化合物的剂量可由医生根据有关的情况来决定。这些情况包括：被治疗者的身体状态、给药途径、年龄、体重、对药物的个体反应，症状的严重程度等。
具体实施方式
下面结合实施例对本发明作进一步的说明。需要说明的是，下述实施例仅是用于说明，而并非用于限制本发明。本领域技术人员根据本发明的教导所做出的各种变化均应在本申请权利要求所要求的保护范围之内。
实施例1
1.66g(10mmol)化合物A-1和2.00g(10mmol)化合物B-1溶解到15mL干燥的MeCN中，再加入4.15g(30mmol)碳酸钾，而后在氮气气氛中加热回流过夜。反应混合物倾倒到冰水中，用50mL×3的二氯甲烷萃取，合并有机相用食盐水洗涤，无水硫酸钠干燥，在旋蒸仪上蒸去溶剂，得到I-1的粗品，柱层析纯化，得到I-1的纯品。MS，m/z＝286([M+H]+).
实施例2
1.66g(10mmol)化合物A-1和2.00g(10mmol)化合物B-1溶解到15mL干燥的DMF中，再加入4.15g(30mmol)碳酸钾和0.2g KI，而后在氮气气氛中120℃过夜。反应混合物倾倒到冰水中，用50mL×3的二氯甲烷萃取，合并有机相用食盐水洗涤，无水硫酸钠干燥，在旋蒸仪上蒸去溶剂，得到I-1的粗品，柱层析纯化，得到I-1的纯品。MS，m/z＝286([M+H]+).
实施例3-10
参照实施例1和2的操作，合成下表中具有式I的化合物。
实施例11
制备工艺：将活性成分和辅料预先粉碎过筛100目，称取主药加辅料乳糖、预胶化淀粉羧甲淀粉钠、和微晶纤维素充分混合，过60目筛三次，加入聚维酮溶液，混合，制软材，过20目筛，制湿颗粒，于50-60℃干燥后，加硬脂酸镁和滑石粉预先过筛，然后加入到上述的颗粒中充分混合后，测定中间体颗粒，压片。
实施例12
制备工艺：将活性成分加辅料乳糖、部分交联聚维酮、微晶纤维素、阿斯巴甜和橘子香精过筛充分混合均匀，加入2％羟丙甲纤维素溶液，混合，制软材，过24目筛，制湿颗粒，于50-60℃干燥后，20目筛整粒。将剩余交联聚维酮、硬脂酸镁和滑石粉过筛后，加入到上述的颗粒中充分混合后，测定中间体颗粒，压片。
实施例13
制备工艺：将主药与辅料分别过100目筛，充分混合，采用辊压机压饼，再用整粒剂过18目筛整粒，最后加入润滑剂硬脂酸镁，混合均匀压片。
实施例14
制备工艺：将活性成分粉碎过100目筛，加辅料甘露醇、山梨醇、甜菊甙和橙皮酊，充分混合，加入5％聚乙二醇6000溶液，混合，制软材，过18目筛，制湿颗粒，于50-60℃干燥后，18目筛整粒。将硬脂酸镁和滑石粉预先过筛，然后加入到上述的颗粒中充分混合后，测定中间体颗粒，压片。
实施例15
制备工艺：将主药与辅料分别过100目筛，充分混合，然后称取处方量辅料与主药充分混合。再加入粘合剂制软材，14目筛制粒，55℃干燥，12目筛整粒，测定袋重包装。
实施例16
制备工艺：取注射用水80ml，加主药、甘露醇、乳糖、泊洛沙姆搅拌使溶解后，加1mol/L的枸橼酸调节PH至7.0-9.0，补加水至100ml。加入0.5g活性炭，在30℃下搅拌20分钟，脱炭，采用微孔滤膜过滤除菌，滤液按每支1ml进行分装，预冻2小时后，冷冻下减压干燥12小时，至样品温度到室温后，再干燥5小时，制得白色疏松块状物，封口即得。
实施例17
制备工艺：取注射用水100ml，加主药、焦亚硫酸钠、碳酸氢钠搅拌使溶解后，加适量氢氧化钠调节PH为7.0-9.0，补加注射用水至200ml，加入2g活性炭，搅拌吸附30分钟，除炭、精滤、以每支2ml灌封、灭菌，即得。
实施例18
制备工艺：取注射用水2000ml，加主药、三羟甲基氨基甲烷、低分子右旋糖苷、EDTA-2Na搅拌使溶解后，用碳酸氢钠调节PH为7.0-9.0，加入10g活性炭，在20-50℃下搅拌吸附30分钟，除炭，补加水至5000ml，精滤、灌封每瓶50ml，灭菌，即得。
实施例19
(1)材料
细胞株：白血病HL-60细胞、胃腺癌SGC-7901细胞、乳腺癌MCF-7细胞、肺癌A-549细胞，均购自中国科学院上海细胞研究所。
试剂：MTT，Amresco分装；DMEM培养基，Gibco；小牛血清，兰州民海生物；胰蛋白酶，Amresco分装；氟尿嘧啶注射液，0.25g/10ml(支)，天津金耀氨基酸有限公司。
仪器：超净工作台，苏州净化设备厂；CO2培养箱，Thermo公司，型号：HERA Cell150；倒置显微镜，Carl Zeiss公司，型号：Axiovert 200；酶联免疫检测仪，TECAN公司，型号：Sunrise；离心机，Kerdro公司，型号：Heraeus。
(2)方法
细胞培养：肿瘤细胞接种在含10％小牛血清，100IU/ml青霉素G钠盐及100ug/ml硫酸链霉素的DMEM培养液中，置37℃、100％相对湿度、含5％CO2的培养箱中，传代3次后备用。
MTT法测定：取对数生长期的细胞，经0.25％胰蛋白酶消化后(悬浮细胞无须消化)，悬浮于含10％小牛血清的DMEM培养液中，用玻璃滴管轻轻吹打成单细胞悬液，显微镜下用血细胞记数板记数活细胞。96孔培养板每孔接种细胞悬液90μl(细胞浓度调整为6～8×104个/ml)，在37℃、100％相对湿度、含5％CO2、95％空气的培养箱培养24h后，每孔加5μl药液(终浓度为10μg/ml)。另外，每个浓度设阴性对照(等浓度DMSO)及空白本底(不加细胞)，各组均设6个复孔。再连续培养48h，然后每孔加入10μl5mg/ml的MTT溶液，继续培养4h后，仔细吸去上清液(悬浮细胞，需要先离心，再吸去上清)。每孔加入100μl DMSO，置微量振荡器震荡以使结晶完全溶解，酶标仪492nm单波长比色，测定OD值。以下述方法计算细胞生长抑制率作为评价指标。
抑制率(％)＝[1-(实验组OD均值-空白组OD均值)/(对照组OD均值-空白组OD均值)]×100％。
(3)结果
表1.样品对体外培养肿瘤细胞的抑制率(％)
(4)结论
从上述体外试验结果可以看出，本发明所述通式I化合物在10μg/ml浓度时体外作用48h后对这4种人类癌细胞均具有较强的抑制作用。
Claims (7)
1.具有通式I的化合物或其药学上可接受的盐：
其中，
R1和R2独立地选自H，C1-C5的烷基，苯基，被F、Cl、Br、I、CN、NO2、C1-C5的烷基取代的苯基；
n＝0-5。
2.权利要求1所定义的具有通式I的化合物或其药学上可接受的盐：
其中，
R1和R2独立地选自H，C1-C3的烷基，苯基，被F、Cl、CN、NO2、C1-C3的烷基取代的苯基；
n＝1-3。
3.权利要求1所定义的通式I化合物或其药学上可接受的盐，选自：
4.合成权利要求1-3之一所定义的通式I化合物的方法，包括以下步骤：
化合物A和化合物B在碱存在下在合适的溶剂中反应，可以得到化合物I；
其中所述碱选自三乙胺、二异丙基乙基胺、KOH、NaOH、碳酸钾、碳酸钠、乙醇钠、氢化钠，溶剂选自三氯甲烷、二氯甲烷、乙腈、DMF；当溶剂为DMF时，该反应使用碘盐作为催化剂，选自KI和NaI。
5.权利要求1-3之一所定义的通式I化合物在制备抗肿瘤药物方面的应用。
6.一种药物组合物，含有权利要求1-3之一的通式I化合物以及药学上可接受的辅料。
7.权利要求6所述的药物组合物，其中，所述的组合物为固体口服制剂、注射制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310192334.9A CN103232394B (zh) | 2013-05-14 | 2013-05-14 | 含吡唑类化合物、其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310192334.9A CN103232394B (zh) | 2013-05-14 | 2013-05-14 | 含吡唑类化合物、其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103232394A CN103232394A (zh) | 2013-08-07 |
| CN103232394B true CN103232394B (zh) | 2014-09-24 |
Family
ID=48880475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310192334.9A Expired - Fee Related CN103232394B (zh) | 2013-05-14 | 2013-05-14 | 含吡唑类化合物、其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103232394B (zh) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2219670T3 (es) * | 1994-11-10 | 2004-12-01 | Millennium Pharmaceuticals, Inc. | Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis. |
| CA2379421A1 (en) * | 1999-08-27 | 2001-03-08 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| CN1968933A (zh) * | 2004-04-21 | 2007-05-23 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的吡唑衍生物 |
| AU2007267097A1 (en) * | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals B.V. | Sulphur containing pyrazole derivatives as selective cannabinoid CB1 receptor antagonists |
| KR101663637B1 (ko) * | 2009-11-13 | 2016-10-07 | 제노스코 | 키나아제 억제제 |
| CN102603637A (zh) * | 2012-01-18 | 2012-07-25 | 中国药科大学 | 吡唑化合物及其作为rtk和pi3k双重抑制剂的用途 |
-
2013
- 2013-05-14 CN CN201310192334.9A patent/CN103232394B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103232394A (zh) | 2013-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111100006B (zh) | 一种3-咖啡酰奎尼酸衍生物及其制备方法和用途 | |
| CN107098909B (zh) | 烷氧端基寡peg修饰的氨基嘧啶衍生物及抗肿瘤应用 | |
| CN113387872B (zh) | 化合物的制备方法及其应用 | |
| CN110869027A (zh) | 异戊酰螺旋霉素i、ii和/或iii在制备治疗和/或预防肿瘤药物方面的应用和药物 | |
| WO2011131034A1 (zh) | 4'-去甲基表鬼臼毒素衍生物及其合成方法和应用 | |
| US11242354B2 (en) | 4-sulfur substituted podophyllotoxin derivative and preparation method therefor and use thereof | |
| CN110857295B (zh) | 具有选择性抗肝癌作用的黄酮-川芎嗪类化合物ch-x及其制备方法和应用 | |
| CN103232394B (zh) | 含吡唑类化合物、其制备方法和用途 | |
| CN103396400B (zh) | 含吡唑酰胺类化合物、其制备方法和用途 | |
| CN100422189C (zh) | 塔斯品碱的制备方法以及在制备治疗肿瘤药物中的应用 | |
| CN103265535B (zh) | 抗肿瘤化合物、其制备方法和用途 | |
| CN104292210B (zh) | 含吡啶的一氧化氮供体类化合物、其制备方法及用途 | |
| CN103435573B (zh) | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 | |
| CN103387568B (zh) | 一类化合物、其制备方法和用途 | |
| CN103265537B (zh) | 抗肿瘤化合物、其制备方法和用途 | |
| CN103420993B (zh) | 含噻吩取代的化合物、其制备方法和用途 | |
| CN103387569B (zh) | 一类抗肿瘤化合物、其制备方法和用途 | |
| CN103382198B (zh) | 吡唑酰胺类化合物、其制备方法和用途 | |
| CN103435572B (zh) | 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途 | |
| CN103382202B (zh) | 含呋喃取代的化合物、其制备方法和用途 | |
| CN108276369B (zh) | 多硫代赤霉酸酯类化合物及其制备方法与抗肿瘤用途 | |
| CN104119295B (zh) | 吩噻嗪类一氧化氮供体、其制备方法和用途 | |
| CN103382190B (zh) | 一类噻唑并环己烷类化合物、其制备方法和用途 | |
| CN116574141A (zh) | 二茂铁甲酸和生物碱复盐及其制备方法和用途 | |
| CN102417514B (zh) | 吡啶衍生物、其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140924 Termination date: 20160514 |